- Home
- KLTO vs ADTX Comparison
KLTO vs ADTX Comparison
Compare KLTO & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- ADTX
- Stock Information
- Founded
- KLTO 2019
- ADTX 2017
- Country
- KLTO United States
- ADTX United States
- Employees
- KLTO N/A
- ADTX N/A
- Industry
- KLTO
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- ADTX Health Care
- Exchange
- KLTO NYSE
- ADTX Nasdaq
- Market Cap
- KLTO 4.8M
- ADTX 5.3M
- IPO Year
- KLTO N/A
- ADTX 2020
- Fundamental
- Price
- KLTO $0.22
- ADTX $1.66
- Analyst Decision
- KLTO
- ADTX
- Analyst Count
- KLTO 0
- ADTX 0
- Target Price
- KLTO N/A
- ADTX N/A
- AVG Volume (30 Days)
- KLTO 31.8M
- ADTX 215.2K
- Earning Date
- KLTO 05-15-2025
- ADTX 05-27-2025
- Dividend Yield
- KLTO N/A
- ADTX N/A
- EPS Growth
- KLTO N/A
- ADTX N/A
- EPS
- KLTO N/A
- ADTX N/A
- Revenue
- KLTO N/A
- ADTX $55,323.00
- Revenue This Year
- KLTO N/A
- ADTX $15,768.94
- Revenue Next Year
- KLTO N/A
- ADTX N/A
- P/E Ratio
- KLTO N/A
- ADTX N/A
- Revenue Growth
- KLTO N/A
- ADTX N/A
- 52 Week Low
- KLTO $0.11
- ADTX $2.04
- 52 Week High
- KLTO $13.10
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- ADTX 29.72
- Support Level
- KLTO N/A
- ADTX $1.57
- Resistance Level
- KLTO N/A
- ADTX $1.85
- Average True Range (ATR)
- KLTO 0.00
- ADTX 0.22
- MACD
- KLTO 0.00
- ADTX 0.28
- Stochastic Oscillator
- KLTO 0.00
- ADTX 12.00
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.